Skip to content

Maxcyte, Inc.

MXCT· NasdaqCore metricsCIK 1287098

Commercial physical & biological research16 peers

Last sale
Nov 12, 2026 · +7.27%
Market cap
$121.84M
103.25M shares
Filings
338
$6.20M
Q3 2026−14.5% FY25 yoy
-$4.76M
Q3 2026N/M FY25 yoy
-$6.04M
Q3 2026N/M FY25 yoy
-$18.53M
Q3 2026derivedN/M FY25 yoy
-$0.05
Q3 2026N/M FY25 yoy
$13.37M
Q3 2026−28.0% FY25 yoy
$121.84M
—
3.8×
0.8×
-17.60%
—

Twelve months to Sep 30, 2026 · derived

Price

$1.1823.87%$0.37past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$33.03MFY 2025
$38.63M0FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$33,026,000reported
FY 20242024-12-31$38,627,000reported
FY 20232023-12-31$19,497,000reported
FY 20222022-12-31$28,748,000 revisedreported
FY 20212021-12-31$21,571,400reported
FY 20202020-12-31$15,451,500reported
FY 20192019-12-31$13,257,200reported

Segments

Revenue by Geography, FY2023 to FY2025FY2023Inside the United States · FY2023 · $32.42MOutside the United States · FY2023 · $8.87MFY2024Inside the United States · FY2024 · $25.77MOutside the United States · FY2024 · $12.86MFY2025Inside the United States · FY2025 · $21.08MOutside the United States · FY2025 · $11.95M
LineFY2025ShareChange
Inside the United States$21.08M64%−18.2%
Outside the United States$11.95M36%−7.1%
Total$33.03M

From the 10-K filed Mar 25, 2026MXCT

Commercial physical & biological research

Maxcyte, Inc. is the 7th largest of the 17 covered companies the SEC files under this code, by revenue. SIC 8731

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Maxcyte, Inc. · CIK 1287098 · Engraved from SEC EDGAR